Ketamine sublingual - iX Biopharma

Drug Profile

Ketamine sublingual - iX Biopharma

Alternative Names: Ketamine wafer - iX Biopharma; Wafermine

Latest Information Update: 19 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator iX Biopharma
  • Class Analgesics; Cyclohexanes; General anaesthetics; Small molecules
  • Mechanism of Action NMDA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Acute pain; Dental pain; Pain

Most Recent Events

  • 24 Aug 2017 iX Biopharma initiates a phase II trial for Acute pain in USA (NCT03246971)
  • 04 Mar 2017 iX Biopharma completes enrolment in its clinical trial in Healthy volunteers in Australia (ACTRN12617000140358)
  • 13 Feb 2017 iX Biopharma initiates enrolment in a bioavailability clinical trial in Healthy volunteers in Australia (ACTRN12617000140358)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top